Interferons, immunity and cancer immunoediting
The DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index.
Abstract
A clear picture of the dynamic relationship between the host immune system and cancer is emerging as the cells and molecules that participate in naturally occurring antitumour immune responses are being identified. The interferons (IFNs) - that is, the type I IFNs (IFNalpha and IFNbeta) and type II IFN (IFNgamma) - have emerged as central coordinators of tumour-immune-system interactions. Indeed, the decade-old finding that IFNgamma has a pivotal role in promoting antitumour responses became the focus for a renewed interest in the largely abandoned concept of cancer immunosurveillance. More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a cytokine which promotes increased tumour immunogenicity and often used to assess T-cell activation31”
From Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis (2016) · cites this paper as [31]
Citations
Cites
1 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577 · cited 1×
“However, it remains unclear whether the tumour-suppressor functions of RNaseL depend on IFN”
BackgroundRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Using a combination of histological and gene-expression analyses, Galon et al”
MethodCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Self-citationCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×
“These pathways coordinately defend cells from the oncogenic and/or genotoxic stimuli that can lead to malignant transformatio”
BackgroundHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932 · cited 1×
“Detailed reviews of IFN biology have been published elsewher”
BackgroundSelf-citationMechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citation
Research works printed but not linked: 1
- Yang, J., Murphy, T. L., Ouyang, W. & Murphy, K. M. Induction of interferon-γ production in TH1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur. J. Immunol. 29, 548–555 (1999). · DOI · Paper page
Cited by
Items 201–300 of 1,002
Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
Gadina, M., Johnson, C., Schwartz, D., Bonelli, M., Hasni, S., Kanno, Y., Changelian, P., Laurence, A., & O’Shea, J. J. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0218-084r · Cited by 159
Muñoz, D. P., Yannone, S. M., Daemen, A., Sun, Y., Vakar-Lopez, F., Kawahara, M., Freund, A. M., Rodier, F., Wu, J. D., Desprez, P.-Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124716 · Cited by 162
“This corroborates previously observed effects of shed NKG2D-Ls (56, 57, 66, 67, 72) and likely involves the non-cell-autonomous activities of other SASP factors, including TGF-β (60, 73–76), especially in the context of p53-deficient and/or oncogene-activated SnCs that develop an amplified secretome (12).”
Berghuis, D., Santos, S. J., Baelde, H. J., Taminiau, A. H., Maarten Egeler, R., Schilham, M. W., Hogendoorn, P. C., & Lankester, A. C. (2011) · The Journal of Pathology · doi:10.1002/path.2819 · Cited by 159
Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis
Labidi‐Galy, S. I., Treilleux, I., Goddard‐Léon, S., Combes, J., Blay, J., Ray-Coquard, I. L., Caux, C., & Bendriss‐Vermare, N. (2012) · OncoImmunology · doi:10.4161/onci.18801 · Cited by 162
“The critical role of type I IFNs in anti-tumor immunosurveillance is also well demonstrated in IFNa receptor 1-deficient mice where tumor growth is exacerbated.(7) IFNa has also direct antitumor activities in OC in vitro and in vivo either in nude mice when associated to paclitaxel or in patients with minimal residual…”
BackgroundTrial watch: Peptide-based vaccines in anticancer therapy
Bezu, L., Kepp, O., Cerrato, G., Pol, J., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1511506 · Cited by 155
“potentially antigenic proteins, and/or because they establish an immunosuppressive milieu that enforces local tolerance.(111-116) Thus, besides a few exceptions and despite promising preclinical findings,(117)multiple studies demonstrate that peptide-based vac-”
BackgroundIFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting
Takeda, K., Nakayama, M., Hayakawa, Y., Kojima, Y., Ikeda, H., Imai, N., Ogasawara, K., Okumura, K., Thomas, D. M., & Smyth, M. J. (2017) · Nature Communications · doi:10.1038/ncomms14607 · Cited by 156
“Both cytotoxic activity and IFN-g production by CTL recognizing tumours are critical for cancer immunoediting, however, whether IFN-g is anti-tumorigenic 5–11 or pro-tumorigenic 12–16 remains controversial 17–19 .”
Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer
Yan, J., Smyth, M. J., & Teng, M. W. L. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028530 · Cited by 149
“The requirement for host IL-12 and its downstream cytokine in activating antitumor immunity is well recognized and has been previously reviewed extensively (Colombo and Trinchieri 2002; Dunn et al. 2006; Tugues et al. 2015).”
BackgroundDendritic Cell-Based Vaccines: Barriers and Opportunities
Cintolo, J. A., Datta, J., Mathew, S. J., & Czerniecki, B. J. (2012) · Future Oncology · doi:10.2217/fon.12.125 · Cited by 152
Wang, R., Wang, C., Lu, L., Yuan, F., & He, F. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107032 · Cited by 161
Current approaches in dendritic cell generation and future implications for cancer immunotherapy
Tuyaerts, S., Aerts, J. L., Corthals, J., Neyns, B., Heirman, C., Breckpot, K., Thielemans, K., & Bonehill, A. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0334-z · Cited by 177
“tumor cells (immunoediting) and suppression of the immune system [53, 205].”
Zuo, B., Zhang, Y., Zhao, K., Wu, L., Qi, H., Yang, R., Gao, X., Geng, M., Wu, Y., Jing, R., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01266-8 · Cited by 155
“3d–f), indicating the generation of de novo T cell responses to epitopes that were not directly presented by DEXP&A2&N. Consistently, interferon-γ (IFN-γ)-expressing CD8+ effector T cells and the level of IFN-γ were significantly elevated in blood from DEXP&A2&N-treated mice compared to DEXP&A2 and PBS groups (Additio…”
BackgroundInfluentialTargeting Tumor-Infiltrating Macrophages to Combat Cancer
Panni, R. Z., Linehan, D. C., & DeNardo, D. G. (2013) · Immunotherapy · doi:10.2217/imt.13.102 · Cited by 152
Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases
Lai, Y., & Dong, C. (2015) · International Immunology · doi:10.1093/intimm/dxv063 · Cited by 162
Wu, C.-F., Andzinski, L., Kasnitz, N., Kröger, A., Klawonn, F., Lienenklaus, S., Weiss, S., & Jablonska, J. (2015) · International Journal of Cancer · doi:10.1002/ijc.29444 · Cited by 149
“Endogenous type I IFNs influence primary tumor growth(12,14,15) and are important mediators in cancer immunoediting.(16) Because hosts that lack type I IFN responsiveness show faster growth of primary tumors and enhanced neutrophil mobilization, we wondered whether metastatic processes are influenced under such condit…”
BackgroundZumwalt, T. J., Arnold, M., Goel, A., & Boland, C. R. (2015) · Oncotarget · doi:10.18632/oncotarget.3205 · Cited by 151
Kristensen, V. N., Vaske, C. J., Ursini-Siegel, J., Van Loo, P., Nordgard, S. H., Sachidanandam, R., Sørlie, T., Wärnberg, F., Haakensen, V. D., Helland, Å., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108781108 · Cited by 149
“Some leukocytes exhibit antitumor activity, including CTLs and NK cells (37).”
BackgroundIFNγ signaling integrity in colorectal cancer immunity and immunotherapy
Du, W., Frankel, T. L., Green, M., & Zou, W. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00735-3 · Cited by 143
Frey, B., Rubner, Y., Wunderlich, R., Weiss, E., Pockley, A. G., Fietkau, R., & Gaipl, U. S. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800099811 · Cited by 154
“IFN-alpha and IFN-beta (Type I IFN) and IFN-gamma (type II interferon) might have non-redundant functions in the cancer immune editing process by affecting distinct target-cell populations [82].”
BackgroundChen, W., Lai, Y., Chen, H., Guo, H., Su, I., & Chen, H. H. W. (2013) · Histopathology · doi:10.1111/his.12156 · Cited by 139
Dissecting Interferon-Induced Transcriptional Programs in Human Peripheral Blood Cells
Waddell, S. J., Popper, S. J., Rubins, K. H., Griffiths, M. J., Brown, P. O., Levin, M., & Relman, D. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009753 · Cited by 144
“Interferons are involved in a wide range of clinically important phenomena, ranging from activation of immune responses to infection [14] to cancer suppression [16] to depression [17].”
BackgroundKhodarev, N. N., Minn, A. J., Efimova, E. V., Darga, T. E., Labay, E., Beckett, M., Mauceri, H. J., Roizman, B., & Weichselbaum, R. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1019 · Cited by 143
“The third function of Stat1 is modulation of an immune response, mediated by activation of MHC class I and II molecules and immune-related cytokines (17, 18).”
BackgroundWong, H. K., Mishra, A., Hake, T. S., & Porcu, P. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08852.x · Cited by 155
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
von Locquenghien, M., Rozalén, C., & Celià-Terrassa, T. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143296 · Cited by 150
“IFNs increase the cytotoxic activity of both innate and adaptive immunity (7).”
BackgroundType I and II Interferons in the Anti-Tumor Immune Response
Fenton, S. E., Saleiro, D., & Platanias, L. C. (2021) · Cancers · doi:10.3390/cancers13051037 · Cited by 161
Lv, L., Pan, K., Li, X.-D., She, K.-L., Zhao, J.-J., Wang, W., Chen, J.-G., Chen, Y.-B., Yun, J.-P., & Xia, J.-C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018219 · Cited by 133
“The presence of tumor-infiltrating cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells correlates with improved survival and confers antitumor activity [5].”
BackgroundProapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation
Yang, A., Wilson, N. S., & Ashkenazi, A. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.08.001 · Cited by 144
“Tumors develop various mechanisms to escape anti-tumor innate and adaptive immune surveillance — a process referred to as immunoselection or immunoediting [10].”
BackgroundImmunopathobiology and therapeutic targets related to cytokines in liver diseases
He, Y., Hwang, S., Ahmed, Y. A., Feng, D., Li, N., Ribeiro, M., Lafdil, F., Kisseleva, T., Szabo, G., & Gao, B. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00580-w · Cited by 137
Jin, J., Hu, H., Li, H. S., Yu, J., Xiao, Y., Brittain, G. C., Zou, Q., Cheng, X., Mallette, F. A., Watowich, S. S., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.02.006 · Cited by 138
Swords into plowshares: IL-23 repurposes tumor immune surveillance
Langowski, J. L., Kastelein, R. A., & Oft, M. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.03.006 · Cited by 149
Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer
Zhou, L., Hou, B., Wang, D., Sun, F. Z., Song, R., Shao, Q., Wang, H., Yu, H., & Li, Y. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c01140 · Cited by 140
Kelly, R. J., Lee, J., Bang, Y., Almhanna, K., Blum-Murphy, M. A., Catenacci, D. V. T., Chung, H. C., Wainberg, Z. A., Gibson, M. K., Lee, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2443 · Cited by 144
“7–not reached [NR] (27)) and OS (median, 13.”
Dual biological effects of the cytokines interleukin-10 and interferon-γ
Wilke, C. M., Wei, S., Wang, L., Kryczek, I., Kao, J., & Zou, W. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1104-5 · Cited by 138
The treatment of bladder cancer in a mouse model by epigallocatechin-3-gallate-gold nanoparticles
Hsieh, D.-S., Wang, H., Tan, S.-W., Huang, Y.-H., Tsai, C.-Y., Yeh, M., & Wu, C. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.06.073 · Cited by 138
Tumor associated regulatory dendritic cells
Ma, Y., Shurin, G. V., Gutkin, D. W., & Shurin, M. R. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.010 · Cited by 142
“Due to their ability to secrete high evels of type-I IFN and TNF- , pDCs would appear to have potenial to promote anti-tumor immunity: IFN- has direct anti-tumor ctivities by inhibiting tumor cell proliferation and neoangioenesis and also by promoting immunosurveillance through the ctivation of B cells, NK cells and m…”
BackgroundType I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer
Lan, Q., Peyvandi, S., Duffey, N., Huang, Y.-T., Barras, D., Held, W., Richard, F., Delorenzi, M., Sotiriou, C. P., Desmedt, C., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0624-2 · Cited by 141
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Fridman, W. H., Fucikova, J., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 136
“Thus, in the course of tumor progression malignant cells acquire the ability to harness immunosuppressive mechanisms to their own benefit, hence avoiding recognition and elimination by the host immune system.(15,16) These considerations have driven the development of several immunomodulatory mAbs aimed at activating n…”
BackgroundYin, Y., Feng, W., Chen, J., Chen, X., Wang, G., Wang, S., Xu, X., Nie, Y., Fan, D., Wu, K., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00539-x · Cited by 139
“Additionally, IFN-γ directly induces tumor cell death through anti-proliferative mechanisms and impedes intra-tumoral angiogenesis by inducing chemokines, such as C-X-C motif chemokine ligand 9 (CXCL9), CXCL10, and CXCL11 [71, 72].”
BackgroundThe role of IL-11 in immunity and cancer
Xu, D. H., Zhu, Z., Wakefield, M. R., Xiao, H., Bai, Q., & Fang, Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.004 · Cited by 134
Pancreatic adenocarcinomas with mature blood vessels have better overall survival
Katsuta, E., Qi, Q., Peng, X., Hochwald, S. N., Yan, L., & Takabe, K. (2019) · Scientific Reports · doi:10.1038/s41598-018-37909-5 · Cited by 147
STAT3 inhibitors for cancer therapy: Have all roads been explored?
Fagard, R., Metelev, V., Souissi, I., & Baran-Marszak, F. (2013) · JAK-STAT · doi:10.4161/jkst.22882 · Cited by 129
Novel Insights of Oligometastases and Oligo-Recurrence and Review of the Literature
Niibe, Y., & Chang, J. Y. (2012) · Pulmonary Medicine · doi:10.1155/2012/261096 · Cited by 135
“Interleukin has been reported to play a key role in the growth of micrometastases [24]; it is the switch that results in progression of micrometastases.”
BackgroundClinical Significance of B7‐H1 and B7‐1 Expressions in Pancreatic Carcinoma
Wang, L., Ma, Q., Chen, X., Guo, K., Li, J., & Zhang, M. (2010) · World Journal of Surgery · doi:10.1007/s00268-010-0448-x · Cited by 145
“associated with the mode of tumor immune escape, which consists of complicated mechanisms [21, 22].”
BackgroundMyeloid-Derived Cells in Tumors: Effects of Radiation
Vatner, R. E., & Formenti, S. C. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.008 · Cited by 142
Pylaeva, E., Lang, S., & Jablonska, J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00629 · Cited by 122
“While IFN-γ is known mainly as an agent regulating tumor cell survival, type I IFNs primarily modulate host immune responses against tumors (68).”
BackgroundMpakali, A., & Stratikos, E. (2021) · Cancers · doi:10.3390/cancers13010134 · Cited by 138
Zhang, Y., Sun, Y., Rao, E., Yan, F., Li, Q., Zhang, Y., Silverstein, K. A. T., Liu, S., Sauter, E., Cleary, M. P., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2689 · Cited by 129
“Thus, how to strengthen host immunity to protect against tumor development remains an area of intense research (32, 33).”
BackgroundInterferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4
Mo, X., Zhang, H., Preston, S., Martin, K., Zhou, B., Vadalia, N., Gamero, A. M., Soboloff, J., Tempera, I., & Zaidi, M. R. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1615 · Cited by 119
NK cells in childhood obesity are activated, metabolically stressed, and functionally deficient
Tobin, L. M., Mavinkurve, M., Carolan, E., Kinlen, D., O’Brien, E. C., Little, M. A., Finlay, D. K., Cody, D., Hogan, A. E., & O’Shea, D. (2017) · JCI Insight · doi:10.1172/jci.insight.94939 · Cited by 118
IFITM proteins: Understanding their diverse roles in viral infection, cancer, and immunity
Gómez-Herranz, M., Taylor, J., & Sloan, R. D. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102741 · Cited by 133
Lopès, A., Billard, E., Casse, A. H., Villéger, R., Veziant, J., Roche, G., Carrier, G., Sauvanet, P., Briat, A., Pagès, F., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32920 · Cited by 119
Side population and cancer stem cells: Therapeutic implications
Moserle, L., Ghisi, M., Amadori, A., & Indraccolo, S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.05.020 · Cited by 135
The Side Population of Ovarian Cancer Cells Is a Primary Target of IFN-α Antitumor Effects
Moserle, L., Indraccolo, S., Ghisi, M., Frasson, C., Fortunato, E., Canevari, S., Miotti, S., Tosello, V., Zamarchi, R., Corradin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6341 · Cited by 123
Guo, L., Wang, C., Qiu, X., Pu, X., & Chang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01052 · Cited by 122
“In humans, CD8+ cytotoxic T cells (39), CD4+ cytotoxic T cells (69), and Th1 cells (69) are the most critical subsets producing IFN-γ.”
BackgroundThe Roles of the Methyl-CpG Binding Proteins in Cancer
Parry, L., & Clarke, A. R. (2011) · Genes & Cancer · doi:10.1177/1947601911418499 · Cited by 140
PD‐1/PD‐L1 inhibitors in haematological malignancies: update 2017
Jelinek, T., Mihalyova, J., Kascak, M., Duras, J., & Hajek, R. (2017) · Immunology · doi:10.1111/imm.12788 · Cited by 122
Bill, M. A., Fuchs, J. R., Li, C., Yui, J., Bakan, C., Benson, D. M., Schwartz, E. B., Abdelhamid, D., Lin, J., Hoyt, D. G., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-165 · Cited by 116
“We therefore evaluated whether FLLL32 would affect the responsiveness of PBMCs to stimulation with clinically relevant cytokines that mediate tumor progression (IL 6), immunosurveillance (IFN-γ) or T and NK cell survival (IL 2) [34-36].”
In Vivo Analysis of Ifn-γ1 and Ifn-γ2 Signaling in Zebrafish
Aggad, D., Stein, C., Sieger, D., Mazel, M., Boudinot, P., Herbomel, P., Levraud, J., Lutfalla, G., & Leptin, M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000549 · Cited by 127
He, D., Wu, L., Kim, H. K., Li, H., Elmets, C. A., & Xu, H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804108 · Cited by 121
Wu, Z., Lauer, T. W., Sick, A., Hackett, S. F., & Campochiaro, P. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702321200 · Cited by 118
Increased Soluble CD155 in the Serum of Cancer Patients
Iguchi‐Manaka, A., Okumura, G., Kojima, H., Cho, Y., Hirochika, R., Bando, H., Sato, T., Yoshikawa, H., Hara, H., Shibuya, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152982 · Cited by 119
“Interactions of cell surface receptors with their ligands expressed on tumor cells induce cytotoxic activity of CTL and NK cells against tumors [4].”
BackgroundTumor microenvironment is multifaceted
Sautès‐Fridman, C., Cherfils‐Vicini, J., Damotte, D., Fisson, S., Fridman, W. H., Cremer, I., & Dieu‐Nosjean, M. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9279-y · Cited by 129
“The high frequencies of tumors in rag2 �/� mice [ 11 ] demonstrate the”
BackgroundExpanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and Therapy
Dobrzanski, M. J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00063 · Cited by 124
“Alternatively, a dual role for IFN-γ in the context of malignancy has been reported and associated with contributing to enhanced tumor growth and metastases (Dunn et al., 2006; Schreiber et al., 2011).”
BackgroundA balance of interleukin-12 and -23 in cancer
Ngiow, S. F., Teng, M. W. L., & Smyth, M. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.004 · Cited by 120
Schmitt, M. J., Philippidou, D., Reinsbach, S. E., Margue, C., Wienecke-Baldacchino, A., Nashan, D., Behrmann, I., & Kreis, S. (2012) · Cell Communication and Signaling · doi:10.1186/1478-811x-10-41 · Cited by 113
“IFN-γ has long been recognized for its crucial role in defense against viral and bacterial infections as well as in tumor control [40,41].”
BackgroundBachmann, S. B., Frommel, S. C., Camicia, R., Winkler, H. C., Santoro, R., & Hassa, P. O. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-125 · Cited by 109
“IFNγ/STAT1 signaling is mediated through activation of IFNγ receptor and Janus kinases (JAK) 1 and 2 that lead to tyrosine phosphorylation of STAT1 on Y701, homodimerization and translocation of STAT1 to the nucleus where it induces the transcription of IFNγ-stimulated genes, including the tumor suppressor IRF1 [28].”
BackgroundZhu, D., Hu, C., Fan, F., Qin, Y., Huang, C., Zhang, Z., Lu, L., Wang, H., Sun, H., Leng, X., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.03.012 · Cited by 118
Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model
Piranlioglu, R., Lee, E., Ouzounova, M., Bollag, R. J., Vinyard, A. H., Arbab, A. S., Marasco, D., Güzel, M., Cowell, J. K., Thangaraju, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09015-1 · Cited by 118
Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy
Chen, P.-H., Lipschitz, M., Weirather, J. L., Jacobson, C., Armand, P., Wright, K., Hodi, F. S., Roberts, Z. J., Sievers, S. A., Rossi, J., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.134612 · Cited by 107
“local immunity in a beneficial manner, such as IL-12, IL-15, and IL-18 to promote a Th1 response, or a truncated IL-6 receptor to sequester local IL-6, may augment tumoricidal activity without increasing immune-mediated pathology (23, 43).”
BackgroundGBP-1 acts as a tumor suppressor in colorectal cancer cells
Britzen‐Laurent, N., Lipnik, K., Ocker, M., Naschberger, E., Schellerer, V. S., Croner, R. S., Vieth, M., Waldner, M. J., Steinberg, P., Hohenadl, C., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs310 · Cited by 132
Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers
Moore, E. C., Cash, H. A., Caruso, A. M., Uppaluri, R., Hodge, J. W., Van Waes, C., & Allen, C. T. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0252 · Cited by 106
“The ability of IFNg to upregulate MHC class I expression is well established (27, 28).”
BackgroundNew views on natural killer cell-based immunotherapy for melanoma treatment
Burke, S., Lakshmikanth, T., Colucci, F., & Carbone, E. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.06.003 · Cited by 124
From tumor cell metabolism to tumor immune escape
Villalba, M., Rathore, M. G., López-Royuela, N., Krzywińska, E., Garaude, J., & Allende-Vega, N. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.04.024 · Cited by 119
Functional Properties of CD8+Lymphocytes in Patients with Pleural Plaque and Malignant Mesothelioma
Kumagai-Takei, N., Nishimura, Y., Maeda, M., Hayashi, H., Matsuzaki, H., Lee, S., Kishimoto, T., Fukuoka, K., Nakano, T., & Otsuki, T. (2014) · Journal of Immunology Research · doi:10.1155/2014/670140 · Cited by 110
“Alternatively, the impaired function of CD8 lymphocytes in MM patients might be related to immune suppression by tumor cells [25].”
BackgroundImmuno-oncology combinations: raising the tail of the survival curve
Harris, S. J., Harris, S. J., Brown, J. S., Lopez, J. S., Yap, T. A., Brown, J. S., Lopez, J. S., & Yap, T. A. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0015 · Cited by 114
The tumor suppressor function of STAT1 in breast cancer
Koromilas, A. E., & Sexl, V. (2013) · JAK-STAT · doi:10.4161/jkst.23353 · Cited by 105
“The increased rate of tumor formation in STAT1 mice was attributed to impaired immune surveillance of tumors because these mice fail to respond to IFN-γ and display reduced natural-killer (NK) activity.(8) Mating of STAT1 and p53 mice yields animals with an increased tumor incidence and a broader spectrum of tumors th…”
BackgroundNi, Z., Hassan, M. A. E., Xu, Z., Tao, Y., & Bremner, R. (2008) · Nature Immunology · doi:10.1038/ni.1619 · Cited by 121
Immune escape mechanisms of intraocular tumors
Niederkorn, J. Y. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.06.002 · Cited by 121
Pirozzolo, G., Gisbertz, S. S., Castoro, C., Henegouwen, M. I. V. B., & Scarpa, M. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.07.30 · Cited by 111
Interferon-α in acute myeloid leukemia: an old drug revisited
Anguille, S., Lion, E., Willemen, Y., Tendeloo, V. F. V., Berneman, Z. N., & Smits, E. (2011) · Leukemia · doi:10.1038/leu.2010.324 · Cited by 126
Intestinal inflammation and colorectal cancer: a double-edged sword?
Rizzo, A., Pallone, F., Monteleone, G., & Fantini, M. C. (2011) · PubMed · doi:10.3748/wjg.v17.i26.3092 · Cited by 107
The Relapse of Psoriasis: Mechanisms and Mysteries
Tian, D., & Lai, Y. (2022) · JID Innovations · doi:10.1016/j.xjidi.2022.100116 · Cited by 118
Identification of somatic JAK1 mutations in patients with acute myeloid leukemia
Xiang, Z., Zhao, Y., Mitaksov, V., Fremont, D. H., Kasai, Y., Molitoris, A., Ries, R. E., Miner, T. L., McLellan, M. D., DiPersio, J. F., et al. (2008) · Blood · doi:10.1182/blood-2007-05-090308 · Cited by 106
Matsushita, H., Hosoi, A., Ueha, S., Abe, J., Fujieda, N., Tomura, M., Maekawa, R., Matsushima, K., Ohara, O., & Kakimi, K. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0098 · Cited by 107
“IFNg is a critical cytokine for antitumor immunity under natural and therapeutic conditions (15, 16).”
BackgroundAlshaker, H. A., & Matalka, K. Z. (2011) · Cancer Cell International · doi:10.1186/1475-2867-11-33 · Cited by 132
“Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG: Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing.”
BackgroundInfluentialThe new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
Bechman, K., Yates, M., & Galloway, J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104392 · Cited by 114
Yadav, D., Ngolab, J., Lim, R. S.-H., Krishnamurthy, S., & Bui, J. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.39 · Cited by 102
The crucial regulatory role of type I interferon in inflammatory diseases
Ji, L., Li, T., Chen, H., Yang, Y., Lu, E., Liu, J., Qiao, W., & Chen, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01188-z · Cited by 121
“Subsequently, IFN-Is can bind to the heterodimeric transmembrane interferon alpha receptor (IFNAR)1 and IFNAR2, resulting in signal transducers and activators of transcription, which drive different signaling pathways through various cascades to regulate the inflammation responses [23, 24].”
BackgroundMolecular definition of the pro‐tumorigenic phenotype of glioma‐activated microglia
Ellert‐Miklaszewska, A., Dąbrowski, M., Lipko, M. A., Sliwa, M., Maleszewska, M., & Kaminska, B. (2013) · Glia · doi:10.1002/glia.22510 · Cited by 109
“Considering the crucial roles of macrophage-derived pro-inflammatory cytokines and interferons in shaping of anti-tumor immunity (Dunn et al., 2006; Schreiber et al., 2011), this may explain the failure of launching anti-tumor defence in malignant gliomas.”
BackgroundCao, W., & Bover, L. C. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00867.x · Cited by 113
“Because IFNa is required for the cancer immunoediting process to deter the growth of primary tumors (131, 132), interactions between BST2 and ILT7 that suppress the IFN responses of pDCs may contribute to tumor tolerance (Fig.”
BackgroundTh17 cells and interleukin‐17 increase with poor prognosis in patients with acute myeloid leukemia
Han, Y., Ye, A., Bi, L., Wu, J., Kang, Y., & Zhang, S. (2014) · Cancer Science · doi:10.1111/cas.12459 · Cited by 113
The New Deal: A Potential Role for Secreted Vesicles in Innate Immunity and Tumor Progression
Benito-Martin, A., Di Giannatale, A., Ceder, S., & Peinado, H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00066 · Cited by 100
“J Natl Cancer Inst (1975) 55(6):1461–6.”
BackgroundKoinis, F., Vetsika, E., Aggouraki, D., Skalidaki, E., Koutoulaki, A., Gkioulmpasani, M., Georgoulias, V., & Kotsakis, A. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.026 · Cited by 109
“Cytokines released by tumor cells seem to play a pivotal role in the development of potent immunosuppressive mechanisms by inducing immunosuppressive cells, including myeloid-derived suppressive cells (MDSCs) and regulatory T cells, in both the peripheral blood circulation and the tumor microenvironment.(8,9) MDSCs ar…”
BackgroundTargeting innate sensing in the tumor microenvironment to improve immunotherapy
Liu, Z., Han, C., & Fu, Y. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0341-y · Cited by 111
Kong, J. C. H., Guerra, G. R., Millen, R. M., Roth, S., Xu, H., Neeson, P. J., Darcy, P. K., Kershaw, M. H., Sampurno, S., Malaterre, J., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00075 · Cited by 96
New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene
Puah, B.-P., Jalil, J., Attiq, A., & Kamisah, Y. (2021) · Molecules · doi:10.3390/molecules26133888 · Cited by 106
Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses
Rouas‐Freiss, N., Moreau, P., Menier, C., LeMaoult, J., & Carosella, E. D. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.07.003 · Cited by 104
Fujita, M., Scheurer, M. E., Decker, S. A., McDonald, H. A., Kohanbash, G., Kastenhuber, E. R., Kato, H., Bondy, M. L., Ohlfest, J. R., & Okada, H. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0644 · Cited by 112
“A critical role of type 1 IFNs in cancer development has been shown previously in methylcholanthrene-induced skin tumor model (25), in which the authors primarily focused on the immunoediting process of cancers.”
BackgroundInfluentialShemesh, M., Löchte, S., Piehler, J., & Schreiber, G. (2021) · Science Signaling · doi:10.1126/scisignal.abe4627 · Cited by 110
Cai, M., Xu, Y., Qiu, S., Ju, M., Gao, Q., Li, Y.-W., Zhang, B., Zhou, J., & Fan, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0463 · Cited by 109
Barber, A., Rynda, A., & Sentman, C. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902000 · Cited by 103
Metadata
- Authors
- Dunn, G. P., Koebel, C. M., & Schreiber, R. D.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Schreiber, Robert D.
- Venue
- Nature Reviews Immunology
- Published
- 2006-11
- Volume
- 6
- Issue
- 11
- Pages
- 836-848
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2052313621
- Cited by
- 1,617
- References
- 119
- Citations by year
- 2026: 33 · 2025: 51 · 2024: 87 · 2023: 104 · 2022: 84 · 2021: 94 · 2020: 93 · 2019: 73 · 2018: 85 · 2017: 74 · 2016: 93 · 2015: 100 · 2014: 100 · 2013: 79 · 2012: 76
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- interferon, type I interferon, interferon-gamma, cancer immunoediting, tumor surveillance, antitumor immunity, tumor-immune interactions, interferon-alpha, interferon-beta, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunity, Immunotherapy, Interferons, Neoplasms, Monitoring, Immunologic, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.